WHO vaccine-preventable diseases: monitoring system. 2014 global summary

Last updated 15-Jul-2014 (Data received as of 8-Jul-2014)
Next overall update Fall 2014
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 54'0401 Infant (under 12 months) mortality rate: 22
GDP / capita (US$): 78'7441 Child (under 5 years) mortality rate: 32

Population data in thousands3

  2013  2012  2011  2010  2009  2000  1990  1980 
Total population 5'412  5'303  5'192  5'079  4'964  3'918  3'016  2'415 
Births 54  53  51  50  50  50  55  40 
Surviving infants 53  52  51  50  49  50  55  40 
Pop. less than 5 years 277  269  263  262  259  256  229  194 
Pop. less than 15 years 869  873  877  881  881  841  647  653 
Female 15-49 years 1'453  1'433  1'410  1'387  1'364  1'129  937  695 

Number of reported case

(Click for retrospective incidence data for Singapore)
Diphtheria
Japanese encephalitis
Measles 42  148  50  16  141  143 
Mumps 521  501  452  631  5'981 
Pertussis 24  29  13 
Polio*
Rubella 64  110  158  178  312 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Singapore)
Vaccine year result method % card seen                                                
BCG          99  99  99  99  99  99  85 
DTP1          98  98  98  98  98 
DTP3          97  96  97  97  98  85  84 
HepB_BD          67  68  68 
HepB3          97  96  96  97  97  74 
Hib3         
JapEnc         
MCV          95  95  95  95  96  84  47 
MCV2          95  94  94  93 
PCV1          64 
PCV3         
Pol3          97  96  97  97  98  85  83 
Rota1         
Rota_last         
Rubella1         
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2015

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Singapore)
BCG 99  99  99  99  99  99  99  85 
DTP1 98  98  98  98  98  98  95  94 
DTP3 97  97  96  97  97  98  85  84 
HepB3 97  97  96  96  97  97  74 
HepB_BD 67  67  68  68  70 
Hib3
MCV 95  95  95  95  95  96  84  47 
MCV2 95  95  94  94  93  94 
PCV3
Pol3 97  97  96  97  97  98  85  83 
Rota_last

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
 

Immunization Schedule (2013 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTaP 3, 4, 5, 18 months;
HPV 9-26 (x3 doses); Yes females only
HepB birth; 1, 5-6 months; Yes
MMR 12, 15-18 months; Yes
OPV 3, 4, 5, 18 months; 6-7, 10-11 years; Yes
Pneumo_conj 3, 5, 12 months; Yes
Pneumo_ps Yes high risk groups
Tdap 10-11 years; Yes

Immunizaton indicators

Indicator Expected answer 2013  2012  2011  2010  2009  2008  2007 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR   Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number           NA  2008-2012 
Nº of districts with microplans that include activities to raise immunization coverage number   NA  NA  NA    NA  NA 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR   Yes  Yes  Yes       

System performance

Total Nº districts in country number   NA  NA  NA  NA  NA  NA 
Nº districts with DTP3 coverage >=80% number  
% of districts with DTP3 coverage >=80% From 0 to 100%              
Nº districts with measles (MCV1) coverage >=95% number   NA  NA  NA  NA  NA   
% of districts with MCV1 coverage >=95% From 0 to 100%              

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND   Yes  Yes  No       
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR   Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Estimated percentage of routine vaccines funded by Government From 0 to 100%   NA          NA 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.